Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria

mBio

Volumn 5, Issue 1, 2014, Pages

  Rodionova, Irina A ^a   Schuster, Brian M ^b   Guinn, Kristine M ^b   Sorci, Leonardo ^a,c   Scott, David A ^a   Li, Xiaoqing ^a   Kheterpal, Indu ^d   Shoen, Carolyn ^e   Cynamon, Michael ^e   Locher, Christopher ^f   Rubin, Eric J ^b   Osterman, Andrei L ^a  

^a BURNHAM INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e SYRACUSE VA MEDICAL CENTER   (United States)

^f VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINO ACID; FATTY ACID; PROLINE; PROTEIN NADD; PROTEIN NADE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; SYNTHETASE; TRANSFERASE; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; ARTICLE; BACTERICIDAL ACTIVITY; CELL METABOLISM; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME KINETICS; ENZYME STRUCTURE; FATTY ACID SYNTHESIS; GENE SILENCING; MOLECULAR CLONING; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMIDE SYNTHASES; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; GENES, ESSENTIAL; MICROBIAL VIABILITY; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NAD; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE;

EID: 84903367764     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00747-13     Document Type: Article

References (39)

1. Gerdes SY, Kurnasov OV, Shatalin K, Polanuyer B, Sloutsky R, Vonstein V, Overbeek R, Osterman AL. 2006. Comparative genomics of NAD biosynthesis in Cyanobacteria. J. Bacteriol. 188:3012-3023. http:// dx.doi.org/10.1128/JB.188.8.3012-3023.2006.
2. Osterman AL, Begley TP. 2007. A subsystems-based approach to the identification of drug targets in bacterial pathogens. Prog. Drug Res. 64:, 133-170. http://dx.doi.org/10.1007/978-3-7643-7567-6_6.
3. Sorci L, Blaby I, De Ingeniis J, Gerdes S, Raffaelli N, de Crécy Lagard V, Osterman A. 2010. Genomics-driven reconstruction of Acinetobacter NADmetabolism: insights for antibacterial target selection. J. Biol. Chem. 285:39490-39499. http://dx.doi.org/10.1074/jbc.M110.185629.
4. Sorci L, Blaby IK, Rodionova IA, De Ingeniis J, Tkachenko S, de Crecy-Lagard V, Osterman AL. 2013. Quinolinate salvage and insights for targeting NAD biosynthesis in group A streptococci. J. Bacteriol. 195: 726-732. http://dx.doi.org/10.1128/JB.02002-12.
5. Sorci L, Martynowski D, Rodionov DA, Eyobo Y, Zogaj X, Klose KE, Nikolaev EV, Magni G, Zhang H, Osterman AL. 2009. Nicotinamide mononucleotide synthetase is the key enzyme for an alternative route of NAD biosynthesis in Francisella tularensis. Proc. Natl. Acad. Sci. U. S. A. 106:3083-3088. http://dx.doi.org/10.1073/pnas.0811718106.
6. Sorci L, Pan Y, Eyobo Y, Rodionova I, Huang N, Kurnasov O, Zhong S, MacKerell AD, Jr, Zhang H, Osterman AL. 2009. Targeting NAD biosynthesis in bacterial pathogens: structure-based development of inhibitors of nicotinate mononucleotide adenylyltransferase NadD. Chem. Biol. 16:849-861. http://dx.doi.org/10.1016/j.chembiol.2009.07.006.
7. Gerdes SY, Scholle MD, D'Souza M, Bernal A, Baev MV, Farrell M, Kurnasov OV, Daugherty MD, Mseeh F, Polanuyer BM, Campbell JW, Anantha S, Shatalin KY, Chowdhury SA, Fonstein MY, Osterman AL. 2002. From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. 184:4555-4572. http:// dx.doi.org/10.1128/JB.184.16.4555-4572.2002.
8. Kurnasov OV, Polanuyer BM, Ananta S, Sloutsky R, Tam A, Gerdes SY, Osterman AL. 2002. Ribosylnicotinamide kinase domain of NadR protein: identification and implications in NAD biosynthesis. J. Bacteriol. 184:6906-6917. http://dx.doi.org/10.1128/JB.184.24.6906-6917.2002.
9. Boshoff HI, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park TH, Yun CS, Schnappinger D, Ehrt S, Williams KJ, Barry CE, III. 2008. Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J. Biol. Chem. 283:19329-19341. http://dx.doi.org/10.1074/jbc.M800694200.
10. Bi J, Wang H, Xie J. 2011. Comparative genomics of NAD(P) biosynthesis and novel antibiotic drug targets. J. Cell. Physiol. 226:331-340. http://dx.doi.org/10.1002/jcp.22419.
11. Beste DJ, Hooper T, Stewart G, Bonde B, Avignone-Rossa C, Bushell ME, Wheeler P, Klamt S, Kierzek AM, McFadden J. 2007. GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol. 8:R89. http://dx.doi.org/10.1186/gb-2007-8-5-r89.
12. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/ 10.1126/science.1106753.
13. Cohen J. 2013. Approval of novel TB drug celebrated-with restraint. Science 339:130. http://dx.doi.org/10.1126/science.339.6116.130.
14. Rao SP, Alonso S, Rand L, Dick T, Pethe K. 2008. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 105:11945-11950. http://dx.doi.org/10.1073/pnas.0711697105.
15. Cheng W, Roth J. 1995. Isolation of NAD cycle mutants defective in nicotinamide mononucleotide deamidase in Salmonella typhimurium. J. Bacteriol. 177:6711-6717.
16. + transporter in an intracellular bacterial symbiont related to Chlamydiae. Nature 432: 622-625. http://dx.doi.org/10.1038/nature03131.
17. De Ingeniis J, Kazanov MD, Shatalin K, Gelfand MS, Osterman AL, Sorci L. 2012. Glutamine versus ammonia utilization in the NAD synthetase family. PLoS One 7:e39115. http://dx.doi.org/10.1371/ journal.pone.0039115.
18. Sorci L, Kurnasov O, Rodionov DA, Osterman AL. 2010. Genomics and enzymology of NAD biosynthesis, p 213-257. In Lew M, Hung-Wen L (ed), Comprehensive natural products II. Elsevier, Oxford, United Kingdom.
19. Huang N, Kolhatkar R, Eyobo Y, Sorci L, Rodionova I, Osterman AL, Mackerell AD, Zhang H. 2010. Complexes of bacterial nicotinate mononucleotide adenylyltransferase with inhibitors: implication for structure-based drug design and improvement. J. Med. Chem. 53:5229-5239. http://dx.doi.org/10.1021/jm100377f.
20. Moro WB, Yang Z, Kane TA, Brouillette CG, Brouillette WJ. 2009. Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs). Bioorg. Med. Chem. Lett. 19:2001-2005. http://dx.doi.org/ 10.1016/j.bmcl.2009.02.034.
21. Moro WB, Yang Z, Kane TA, Zhou Q, Harville S, Brouillette CG, Brouillette WJ. 2009. SAR studies for a new class of antibacterial NAD biosynthesis inhibitors. J. Comb. Chem. 11:617-625. http://dx.doi.org/ 10.1021/cc9000357.
22. Velu SE, Cristofoli WA, Garcia GJ, Brouillette CG, Pierson MC, Luan CH, DeLucas LJ, Brouillette WJ. 2003. Tethered dimers as NAD synthetase inhibitors with antibacterial activity. J. Med. Chem. 46:3371-3381. http://dx.doi.org/10.1021/jm030003x.
23. Sassetti CM, Boyd DH, Rubin EJ. 2001. Comprehensive identification of conditionally essential genes in mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 98:12712-12717. http://dx.doi.org/10.1073/pnas.231275498.
24. Sassetti CM, Rubin EJ. 2003. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. U. S. A. 100:12989-12994. http://dx.doi.org/10.1073/pnas.2134250100.
25. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog. 7:e1002251. http://dx.doi.org/10.1371/journal.ppat.1002251.
26. + synthetase from Mycobacterium tuberculosis depends on an amino-terminal nitrilase domain. Res. Microbiol. 156:173-177. http://dx.doi.org/10.1016/ j.resmic.2004.08.011.
27. Bellinzoni M, De Rossi E, Branzoni M, Milano A, Peverali FA, Rizzi M, Riccardi G. 2002. Heterologous expression, purification, and enzymatic activity of Mycobacterium tuberculosis NAD(+) synthetase. Protein Expr. Purif. 25:547-557. http://dx.doi.org/10.1016/S1046-5928(02)00041-4.
28. LaRonde-LeBlanc N, Resto M, Gerratana B. 2009. Regulation of active site coupling in glutamine-dependent NAD(+) synthetase. Nat. Struct. Mol. Biol. 16:421-429. http://dx.doi.org/10.1038/nsmb.1567.
29. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, Alber T, Sassetti CM, Rhee KY, Rubin EJ. 2011. Depletion of antibiotic targets has widely varying effects on growth. Proc. Natl. Acad. Sci. U. S. A. 108: 4176-4181. http://dx.doi.org/10.1073/pnas.1018301108.
30. Overbeek R, Begley T, Butler RM, Choudhuri JV, Chuang HY, Cohoon M, de Crécy-Lagard V, Diaz N, Disz T, Edwards R, Fonstein M, Frank ED, Gerdes S, Glass EM, Goesmann A, Hanson A, Iwata-Reuyl D, Jensen R, Jamshidi N, Krause L, Kubal M, Larsen N, Linke B, McHardy AC, Meyer F, Neuweger H, Olsen G, Olson R, Osterman A, Portnoy V, Pusch GD, Rodionov DA, Rückert C, Steiner J, Stevens R, Thiele I, Vassieva O, Ye Y, Zagnitko O, Vonstein V. 2005. The subsystems approach to genome annotation and its use in the project to annotate 1000 genomes. Nucleic Acids Res. 33:5691-5702. http://dx.doi.org/10.1093/ nar/gki866.
31. Godek CP, Cynamon MH. 1990. In vitro evaluation of nicotinamide riboside analogs against Haemophilus influenzae. Antimicrob. Agents Chemother. 34:1473-1479. http://dx.doi.org/10.1128/AAC.34.8.1473.
32. Zhang X, Kurnasov OV, Karthikeyan S, Grishin NV, Osterman AL, Zhang H. 2003. Structural characterization of a human cytosolic NMN/ NaMN adenylyltransferase and implication in human NAD biosynthesis. J. Biol. Chem. 278:13503-13511. http://dx.doi.org/10.1074/ jbc.M300073200.
33. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW. 2011. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 286:42626-42634. http://dx.doi.org/10.1074/jbc.M111.282046.
34. Parish T, Stoker NG. 2002. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 148:3069-3077.
35. Reichau S, Jiao W, Walker SR, Hutton RD, Baker EN, Parker EJ. 2011. Potent inhibitors of a shikimate pathway enzyme from Mycobacterium tuberculosis: combining mechanism-and modeling-based design. J. Biol. Chem. 286:16197-16207. http://dx.doi.org/10.1074/jbc.M110.211649.
36. + auxotrophy is bacteriocidal for the tubercle bacilli. Mol. Microbiol. 76:365-377. http://dx.doi.org/10.1111/j.1365-2958.2010.07099.x.
37. Pan P, Tonge PJ. 2012. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr. Top. Med. Chem. 12: 672-693. http://dx.doi.org/10.2174/156802612799984535.
38. Ouellet H, Johnston JB, de Montellano PR. 2011. Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis. Trends Microbiol. 19:530-539. http://dx.doi.org/10.1016/j.tim.2011.07.009.
39. Siegrist MS, Unnikrishnan M, McConnell MJ, Borowsky M, Cheng TY, Siddiqi N, Fortune SM, Moody DB, Rubin EJ. 2009. Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc. Natl. Acad. Sci. U. S. A. 106:18792-18797. http://dx.doi.org/10.1073/ pnas.0900589106.